Patients are randomized to receive either the investigational treatment (two-thirds of patients) or the standard of care treatment (one-third of patients). This study compares the efficacy of tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.

NOW ENROLLING SELECT-MDS-1:

Patients are randomized to receive either the investigational treatment (two-thirds of patients) or the standard of care treatment (one-third of patients). This study compares the efficacy of tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.

Trial participant eligibility key criteria:

- 18 years of age and older
- RARA-positive, based on the investigational assay
- Newly diagnosed with very high, high or intermediate risk MDS
- Have not received prior treatment for MDS

Contact your doctor to discuss participation in the SELECT-MDS-1 trial. For more information about the trial visit ClinicalTrials.gov and search NCT04797780.

Tamibarotene is an investigational agent and has not been approved by the FDA as a treatment for any indication.